Evaluation of safety and effectiveness of a multimodal imaging device HWSO-1 through comparison of various retinal images:Huvitz HWSO-1 vs Heidelberg Spectralis and Topcon Maestro II(Prospective, single-center, open-label, single-group, post-marketing clinical trial)

Huvitz0 个研究点目标入组 56 人开始时间: 待定最近更新: 2024年1月22日

适应症

试验速览

暂无简介。

•1) Healthy eyes
•- Adults between the ages of 19 and 80 years old
•- Those who have given written consent to participate in the study
•- General healthy eyes: Spherical Equivalent within ±6.00D, corrected visual acuity of 0.25 or better, intraocular pressure of 21mmHg or less, no clinically significant abnormal findings in the anterior segment/ fundus, eye without a surgery(excluding cataracts and refractive surgery) and ocular diseases eyes that will not effect the result under investigator's decision.
•2) Ocular disease eyes
•- Adults between the ages of 19 and 80 years old
•- Those who have given written consent to participate in the study
•- subjects who require fundus photography due to eye disease such as retinal disease or glaucoma.

•1) Pregnant and lactating women
•2) Eyes with a media opacity(corneal opacity, severe cataract, vitreous opacity, etc.) that may affect the result by the investigator's decision.
•3) Eyes deemed inappropriate by the investigator.

发起方

Huvitz